Search

Displaying results 2131 - 2140 of 8412 in total
  1. Drug

    Gilteritinib

    go.drugbank.com/drugs/DB12141
    ApprovedInvestigational

    This drug was approved after being designed as an orphan drug with a fast track and priority review status.[L4830]

    Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  2. Drug

    Tegoprazan

    go.drugbank.com/drugs/DB16690
    Investigational

    [A234215, A234220] This drug is a potent and high-selective potassium-competitive acid blocker (P-CAB) with a fast onset of action and the ability to control gastric pH for a prolonged period of time. … [A234215, A234220] Tegoprazan’s strong and sustained effect is due to its ability to be slowly cleared from the gastric glands and exertion of effects independent of acid levels.

  3. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.

    Products: Nu-trihexyphenidyl
  4. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. … [A255582] Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970.

    Synonyms: 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid, 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acidInternational brands: Saaz-DS
  5. Drug

    Benzoic acid

    go.drugbank.com/drugs/DB03793
    ApprovedInvestigational

    As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids. … Recent research shows that sodium benzoate may be beneficial as an add-on therapy (1 gram/day) in schizophrenia. Total Positive and Negative Syndrome Scale scores dropped by 21% compared to placebo.

    Mixtures: Prosed/DS
  6. Drug

    Technetium Tc-99m tetrofosmin

    go.drugbank.com/drugs/DB09160
    Approved

    It is a lipophilic technetium phosphine dioxo cation that was formulated into a freeze-dried kit which yields an injection. … The radioisotope, technetium-99m, is chelated by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and which are referred to as tetrofosmin.

    Categories: P-glycoprotein substrates
  7. Drug

    PF-05230907

    go.drugbank.com/drugs/DB18417
    Investigational

    PF-05230907 is a recombinant activated Factor X variant.

  8. Drug

    Ipecac

    go.drugbank.com/drugs/DB13293
    ApprovedWithdrawn

    [L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued. … [L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatas...

  10. Drug

    Imetelstat

    go.drugbank.com/drugs/DB14909
    ApprovedInvestigational

    [erythropoietin]), but primary resistance to these agents is frequent - the median response duration is 18 to 24 months, with most responders (70%) relapsing due to loss of sensitivity of erythroid progenitors